M2 macrophages treatment attenuates clinical severity in EAN
On the 8th day after cultures of M2 macrophages induced by M-CSF and
IL-4 in vitro, we evaluated the proportions of macrophages and M2
macrophages by flow cytometric analysis. The proportions of macrophages
and M2 macrophages were identified as 98.48% ± 0.189% and 94.60% ±
1.407%, respectively (Figure 2a).
M2 macrophages were administered by the caudal vein from days 8 to day
14 p.i. (0.1 ml, 1 × 106 cells, once two days) to
treated EAN mice. Our results showed that that the clinical scores of
EAN were significantly light in M2 macrophages-treated group from days 8
to day 20 p.i. compared to the control EAN group (p﹤0.05 on each time
point) (Figure 2b). Additionally, the duration of symptoms was markedly
shorter in M2 macrophages treated group than the control group received
PBS.